Attached files
file | filename |
---|---|
8-K - FORM 8-K - Endo International plc | d930606d8k.htm |
EX-23.1 - EX-23.1 - Endo International plc | d930606dex231.htm |
EX-99.2 - EX-99.2 - Endo International plc | d930606dex992.htm |
EX-23.4 - EX-23.4 - Endo International plc | d930606dex234.htm |
EX-99.4 - EX-99.4 - Endo International plc | d930606dex994.htm |
EX-99.3 - EX-99.3 - Endo International plc | d930606dex993.htm |
EX-99.1 - EX-99.1 - Endo International plc | d930606dex991.htm |
EX-23.2 - EX-23.2 - Endo International plc | d930606dex232.htm |
Exhibit 23.3
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement No. 333-194253 on Form S-8 of Endo International plc of our report dated March 12, 2015, relating to the consolidated financial statements of Par Pharmaceutical Holdings, Inc. and subsidiaries comprised of the consolidated statements of operations, comprehensive (loss) income, stockholders equity, and cash flows for the period July 12, 2012 (Date of Inception) through December 31, 2012 (Successor) (which report expresses an unqualified opinion on the consolidated financial statements and includes an explanatory paragraph referring to the merger transaction with Par Pharmaceutical Companies, Inc. and Sky Growth Acquisition Corporation) appearing in this Current Report on Form 8-K of Endo International plc filed on June 2, 2015.
/s/ DELOITTE & TOUCHE LLP
Philadelphia, Pennsylvania
June 2, 2015